JP2021520391A5 - - Google Patents

Download PDF

Info

Publication number
JP2021520391A5
JP2021520391A5 JP2020554523A JP2020554523A JP2021520391A5 JP 2021520391 A5 JP2021520391 A5 JP 2021520391A5 JP 2020554523 A JP2020554523 A JP 2020554523A JP 2020554523 A JP2020554523 A JP 2020554523A JP 2021520391 A5 JP2021520391 A5 JP 2021520391A5
Authority
JP
Japan
Prior art keywords
sodium
dodecanoyl
decanoyl
acid
glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020554523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520391A (ja
JP7442823B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/058828 external-priority patent/WO2019193204A1/en
Publication of JP2021520391A publication Critical patent/JP2021520391A/ja
Publication of JP2021520391A5 publication Critical patent/JP2021520391A5/ja
Priority to JP2024020483A priority Critical patent/JP7744049B2/ja
Application granted granted Critical
Publication of JP7442823B2 publication Critical patent/JP7442823B2/ja
Priority to JP2025146248A priority patent/JP2025179167A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554523A 2018-04-06 2019-04-08 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物 Active JP7442823B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024020483A JP7744049B2 (ja) 2018-04-06 2024-02-14 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
JP2025146248A JP2025179167A (ja) 2018-04-06 2025-09-03 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18166177 2018-04-06
EP18166177.8 2018-04-06
EP18211296.1 2018-12-10
EP18211296 2018-12-10
PCT/EP2019/058828 WO2019193204A1 (en) 2018-04-06 2019-04-08 Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024020483A Division JP7744049B2 (ja) 2018-04-06 2024-02-14 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物

Publications (3)

Publication Number Publication Date
JP2021520391A JP2021520391A (ja) 2021-08-19
JP2021520391A5 true JP2021520391A5 (cg-RX-API-DMAC7.html) 2021-09-30
JP7442823B2 JP7442823B2 (ja) 2024-03-05

Family

ID=66182513

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020554523A Active JP7442823B2 (ja) 2018-04-06 2019-04-08 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
JP2024020483A Active JP7744049B2 (ja) 2018-04-06 2024-02-14 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
JP2025146248A Pending JP2025179167A (ja) 2018-04-06 2025-09-03 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024020483A Active JP7744049B2 (ja) 2018-04-06 2024-02-14 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
JP2025146248A Pending JP2025179167A (ja) 2018-04-06 2025-09-03 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物

Country Status (4)

Country Link
US (1) US20210087250A1 (cg-RX-API-DMAC7.html)
EP (1) EP3773475A1 (cg-RX-API-DMAC7.html)
JP (3) JP7442823B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019193204A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
EP3897570A1 (en) 2018-12-19 2021-10-27 KRKA, d.d., Novo mesto Pharmaceutical composition comprising glp-1 analogue
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
MX2022001975A (es) * 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
WO2021142736A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Dosing regimen of glp-1
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
WO2021142737A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Compositions and methods for treating non-alcoholic steatohepatitis (nash)
CN118754965A (zh) 2020-05-29 2024-10-11 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用
DK4358995T3 (da) * 2021-06-23 2026-02-02 Scholar Rock Inc Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser
KR20230000682A (ko) * 2021-06-25 2023-01-03 한미약품 주식회사 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드
CA3237751A1 (en) 2021-11-10 2023-05-19 Tyler Brown Ionic liquid compositions
EP4299057A1 (en) * 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) * 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
KR20240118786A (ko) * 2021-12-01 2024-08-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Glp-1 및 gip 수용체 이중 작용제의 약학적 조성물 및 이의 용도
EP4226918A1 (en) * 2022-02-15 2023-08-16 Filip Majewski Pharmaceutical single dosage form for oral delivery of peptides
CN114544812B (zh) * 2022-02-18 2023-06-30 复旦大学附属中山医院 一种代谢组合式标志物在诊断哮喘中的应用
WO2023174433A1 (en) * 2022-03-18 2023-09-21 Smart Pharmaceutical (Suzhou) Co., Ltd. Solid, semisolid, or liquid compositions for augmenting the stability, permeability and bioavailability of active pharmaceutical substances
TW202400219A (zh) * 2022-04-29 2024-01-01 香港商鵬躍醫藥科技有限公司 用於鼻內給藥的索馬魯肽及其鹽的藥物組合物
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用
CN115590826B (zh) * 2022-10-21 2023-12-19 北京安必奇生物科技有限公司 一种活性蛋白黏膜给药制剂及其制备方法和应用
CN115656391B (zh) * 2022-12-12 2023-04-07 哈尔滨吉象隆生物技术有限公司 一种特立帕肽含有的杂质的检测方法
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
CN116407641A (zh) * 2023-01-12 2023-07-11 深圳奥礼生物科技有限公司 多肽稳定剂和药物组合物
TW202444407A (zh) * 2023-03-23 2024-11-16 奧孟亞股份有限公司 一種高生物利用度之口服glp促效劑藥物組合物
TW202440149A (zh) * 2023-03-23 2024-10-16 奧孟亞股份有限公司 口服glp促效劑之藥物組合物
WO2025014889A2 (en) * 2023-07-07 2025-01-16 Procompounding, Llc Semaglutide formulations
WO2025037993A1 (en) 2023-08-13 2025-02-20 Filip Majewski Dosage form for peptide agents
US12589135B2 (en) * 2023-08-21 2026-03-31 Cmpd Licensing, Llc Topical administration of GLP-1 receptor agonists
US20250221990A1 (en) * 2023-08-21 2025-07-10 Cmpd Licensing, Llc Topical administration to the oral cavity
CN119454605B (zh) * 2023-11-30 2025-12-19 深圳奥礼生物科技有限公司 一种实现多肽口服吸收的组合物
AU2024391694A1 (en) 2023-12-01 2026-05-21 Zhongshan Wanhan Pharmaceutical Co., Ltd. Nasal administration composition containing glp-1 receptor agonist, and preparation method therefor and use thereof
AU2025220176A1 (en) * 2024-02-05 2026-07-30 Ix Biopharma Limited Compositions and methods for delivering glp-1 agonists (metabolix)
CN122376711A (zh) * 2024-06-03 2026-07-14 深圳奥礼生物科技有限公司 口服的多肽组合物
CN119454909B (zh) * 2025-01-13 2025-04-08 上海世领制药有限公司 经鼻粘膜给药的胰高血糖素样肽-1受体激动剂的制剂组合物、制备方法、用途及鼻施用器

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
JPS57144214A (en) * 1981-03-03 1982-09-06 Kyoto Yakuhin Kogyo Kk Pharmaceutical preparation for rectum medication
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JPH09208485A (ja) * 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU1617399A (en) * 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
DE69916811T2 (de) 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
WO2003007913A2 (en) 2001-07-20 2003-01-30 Samir Mitragotri Method for oral drug delivery
JP3634340B2 (ja) * 2002-11-29 2005-03-30 フロイント産業株式会社 水性セラック皮膜剤とその製造方法及び該皮膜剤を用いたコーティング食品とその製造方法並びにコーティング医薬品とその製造方法
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ ノルディスク アクティーゼルスカブ 新規なglp−1化合物
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
EP2106790B1 (en) * 2004-03-12 2012-10-24 Biodel, Inc. Rapid acting drug delivery compositions
DK1742616T3 (en) * 2004-04-30 2015-01-12 Abraxis Bioscience Llc The microsphere-discharge-system for the prolonged delivery and methods of making and using the same
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー/エス 遅延性のエキセンディン−4化合物
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性glp−1化合物
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
ES2484796T3 (es) 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
US8377863B2 (en) * 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
AU2010250452B2 (en) 2009-05-20 2014-06-05 Toray Industries, Inc. Cell membrane-permeable peptides
CN102596253B (zh) 2009-09-30 2013-11-06 蒂奥迈里克斯研究与指导有限公司 含有维生素b 亚结构的粘膜粘着聚合物
KR20130100897A (ko) 2010-04-21 2013-09-12 나노메가 메디컬 코포레이션 나노입자의 약제학적 조성물
WO2012112319A1 (en) 2011-02-04 2012-08-23 Aegis Therapeutics, Llc Orally bioavailable peptide drug compositions and methods thereof
CN102120781B (zh) * 2011-03-16 2013-07-17 中国药科大学 一种新型胰岛素口服纳米粒的制备及应用
CN103458873B (zh) 2011-04-14 2016-04-13 诺沃—诺迪斯克有限公司 用于口服肽递送的脂肪酸酰化的氨基酸
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Glp-1 펩티드의 조성물 및 그것의 제조
CA2872314C (en) 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
US20150174076A1 (en) 2012-06-14 2015-06-25 Entrega, Inc. Mucoadhesive devices for delivery of active agents
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー/エス 医療用のglp−1/グルカゴン受容体コアゴニスト
EP3359181A1 (en) * 2015-10-07 2018-08-15 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide drugs
JPWO2017183559A1 (ja) * 2016-04-19 2019-02-21 学校法人神戸学院 薬物の経粘膜吸収促進剤

Similar Documents

Publication Publication Date Title
JP2025179167A5 (cg-RX-API-DMAC7.html)
JP2017531665A5 (cg-RX-API-DMAC7.html)
RU2017115651A (ru) Фармацевтические составы для пероральной доставки пептидных или белковых лекарственных средств
US12303598B2 (en) Pharmaceutical composition comprising a GLP-1-agonist and methionine
JP2018529749A5 (cg-RX-API-DMAC7.html)
US6440930B1 (en) Protein formulations
RU2327484C2 (ru) Фармацевтическая композиция для назального всасывания
US8088731B2 (en) Use of GLP-1 compound for treatment of critically ill patients
US6573237B2 (en) Protein formulations
ES2247676T3 (es) Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia.
JP2008500345A (ja) 増加された安定度をもつ生体分子含有調製物
AU2013286177A1 (en) Use of long-acting GLP-1 peptides
CN108135962A (zh) 用于口服递送肽类药物的药物制剂
JP2022132375A (ja) ペプチド送達のための医薬組成物
ES3019509T3 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
US20240299552A1 (en) Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
KR101149454B1 (ko) 생리활성 펩티드의 액상 제제
EP4631514A1 (en) Oral polypeptide composition and use thereof
US20210371489A1 (en) Site 2 single-chain insulin analogues
EP4292583A1 (en) Composition in which absorbability of poorly-absorbable drug is improved
KR102954604B1 (ko) 인간 부갑상선 호르몬(pth)의 제형 및 그 제조 방법
HK40096841A (en) A polypeptide composition, medicament, pharmaceutical composition and application thereof